These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26116886)

  • 21. Histone deacetylases--an important class of cellular regulators with a variety of functions.
    Hildmann C; Riester D; Schwienhorst A
    Appl Microbiol Biotechnol; 2007 Jun; 75(3):487-97. PubMed ID: 17377789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase: a potential therapeutic target for fibrotic disorders.
    Pang M; Zhuang S
    J Pharmacol Exp Ther; 2010 Nov; 335(2):266-72. PubMed ID: 20719940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The roles of histone deacetylases in kidney development and disease.
    Liu H
    Clin Exp Nephrol; 2021 Mar; 25(3):215-223. PubMed ID: 33398599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
    Eom GH; Kook H
    Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the correct HDAC(s) to treat cognitive disorders.
    Fischer A; Sananbenesi F; Mungenast A; Tsai LH
    Trends Pharmacol Sci; 2010 Dec; 31(12):605-17. PubMed ID: 20980063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The emerging role of histone deacetylases (HDACs) in UPR regulation.
    Kahali S; Sarcar B; Chinnaiyan P
    Methods Enzymol; 2011; 490():159-74. PubMed ID: 21266250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?
    Grayson DR; Kundakovic M; Sharma RP
    Mol Pharmacol; 2010 Feb; 77(2):126-35. PubMed ID: 19917878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29.
    Mannaerts I; Eysackers N; Onyema OO; Van Beneden K; Valente S; Mai A; Odenthal M; van Grunsven LA
    PLoS One; 2013; 8(1):e55786. PubMed ID: 23383282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic repression of matrix metalloproteinases in myofibroblastic hepatic stellate cells through histone deacetylases 4: implication in tissue fibrosis.
    Qin L; Han YP
    Am J Pathol; 2010 Oct; 177(4):1915-28. PubMed ID: 20847282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone Deacetylase Modifications by Probiotics in Colorectal Cancer.
    Salek Farrokhi A; Mohammadlou M; Abdollahi M; Eslami M; Yousefi B
    J Gastrointest Cancer; 2020 Sep; 51(3):754-764. PubMed ID: 31808058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptional dysregulation in Huntington's disease: The role of histone deacetylases.
    Sharma S; Taliyan R
    Pharmacol Res; 2015 Oct; 100():157-69. PubMed ID: 26254871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.
    Hadnagy A; Beaulieu R; Balicki D
    Mol Cancer Ther; 2008 Apr; 7(4):740-8. PubMed ID: 18413789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
    Konsoula Z; Barile FA
    J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis.
    Zhou B; Margariti A; Zeng L; Xu Q
    Cardiovasc Res; 2011 Jun; 90(3):413-20. PubMed ID: 21233251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.
    Bassett SA; Barnett MP
    Nutrients; 2014 Oct; 6(10):4273-301. PubMed ID: 25322459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
    Korfei M; Mahavadi P; Guenther A
    Cells; 2022 May; 11(10):. PubMed ID: 35626663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is there any therapeutic value for the use of histone deacetylase inhibitors for chronic pain?
    Wang W; Cui SS; Lu R; Zhang H
    Brain Res Bull; 2016 Jul; 125():44-52. PubMed ID: 27090944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats.
    Kang SH; Seok YM; Song MJ; Lee HA; Kurz T; Kim I
    Mol Pharmacol; 2015 May; 87(5):782-91. PubMed ID: 25667225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.